Business Wire

ActiveViam’s Atoti Powers SEB’s New P&L Sentinel for Streamlined Trading Desk Oversight

20.5.2025 09:00:00 CEST | Business Wire | Press Release

Share

ActiveViam, a global provider of advanced data analytics and decision-making solutions for the Financial Services industry, announced today that SEB AB, the leading Nordic corporate bank, has implemented and rolled out Atoti, ActiveViam's flagship product, as their P&L reporting solution.

Replacing a previous technology that was heavily based on spreadsheets and ad-hoc procedures, Atoti is now being used to investigate and report Actual P&L, create adjustments, and perform sign-off on aggregated P&L figures. The application called P&L Sentinel supports P&L Control and fifteen trading desks covering all traded assets of SEB.

Atoti's multidimensional cubes together with its distributed data architecture, allows SEB to have on-the-fly access from the top of house to the most granular trade details with access to historical data within forty business days, as well as aggregated historical data by portfolio supporting MTD, QTD, and YTD calculations.

Atoti Sign Off, a module in the Atoti product suite, has also been deployed to oversee and control the bank's daily internal approval and reporting operations satisfying the needs of internal stakeholders (P&L Control and Front Office).

All this is brought together under Atoti UI providing SEB with a unified and flexible set of dashboards. These support not only analytics and reporting but also the end-of-day approval process. These were configured so as to adhere to the firm's standards for workflow and approval.

SEB Head of Market Risk, Rasoul Najafi said: “We have successfully implemented P&L Sentinel within Atoti, modernizing our P&L management with a workflow-driven platform.

"This enables us to efficiently control and report daily trading P&L while providing enhanced drill-down capabilities. Both front office traders and risk controllers can seamlessly analyze figures at various levels. The solution brings improved oversight, transparency, and adaptability to our P&L processes.”

Shelly Magee, CEO of ActiveViam added, "We are delighted to expand our partnership with SEB with a long term commitment to support not only their liquidity but also their P&L reporting and operational workflow. This was a challenging, large-scale deployment of Atoti on the cloud and, together, we have built a world class application."

About SEB
SEB is one of the largest banks in Sweden, along with Svenska Handelsbanken and Swedbank. SEB is also the leading Nordic corporate bank. The bank was founded in 1856 and has a long history in the banking industry. In 1964, SEB released the Eurocard credit card, which was an alternative to American Express.

About ActiveViam
ActiveViam is a fast-growing financial data analytics solution provider.

Built for and trusted by leading financial institutions, ActiveViam delivers active intelligence for complex financial analytics.

It combines unrivaled technology, continuous innovation and exceptional people to unlock the power of real-time and granular data at scale.

Designed as a high-performance semantic layer, ActiveViam’s flagship product Atoti, allows clients to implement built-in front office and risk business solutions while accessing customizable technology.

ActiveViam is present in the world’s leading financial marketplaces: London, New York, Singapore, Sydney, Hong Kong, Paris and Frankfurt.

For more information, please visit: activeviam.com or follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520048578/en/

Contacts

Press inquiries:
Hervé de Laforcade, Chief Marketing Officer, ActiveViam
hla@activeviam.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye